Idiopathic pulmonary fibrosis: state of the art for 2023
The DOI matches its Crossref record; 188 of the 196 references it cites were found in a registry or an index.
Abstract
Review noting that IPF is a progressive fibrotic lung disease characterized by worsening respiratory symptoms and physiological impairment, while the individual patient course and rate of disease progression are often unpredictable and heterogeneous.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to now, the specific therapeutic drugs that reverse IPF or halt the progression of IPF are still unavailable due to the incomplete understanding of the pathogenesis of IPF 5.”
From Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice (2024) · cites this paper as [5]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citation(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation
Research works printed but not linked: 1
- 10.1186/s12931-019 · doi:10.1186/s12931-019
Cited by
Items 101–200 of 354
Advances in cGAS-STING Signaling in Fibrosis Diseases: Therapeutic Target in Pathological Scars
Zhao, W., Angspatt, A., Kitkumthorn, N., & Meevassana, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s541656 · Cited by 7
“86,87 The current understanding of PF pathogenesis is that it results from an abnormal wound-healing response in lung tissue, triggered by various disease-specific factors.”
Yanlin, Z., Wang, Y., Wang, M., Li, B., Xu, K., Pan, X., Li, Z., Wang, Q., He, W., Pang, J., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01373-5 · Cited by 5
“IPF is a chronic, progressive lung disease characterized by scarring of lung tissue, severely impacting both quality of life and prognosis(Podolanczuk et al. 2023; Bonella et al. 2023).”
Kanne, J. P., Walker, C. M., Brixey, A. G., Brown, K. K., Chelala, L., Kazerooni, E. A., Walsh, S. L. F., & Lynch, D. A. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31125 · Cited by 8
Xie, D., Wang, P., Chen, W., Lin, J., Wu, M., Wang, Y., Xia, H., Cheng, C., Ye, F., Syed, B. M., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111029 · Cited by 6
Zhang, H., Hua, H., Wang, C., Zhu, C., Xia, Q., Jiang, W., Hu, X., & Zhang, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03249-6 · Cited by 7
Tonelli, R., Smit, M. R., Castaniere, I., Casa, G. D., Andrisani, D., Gozzi, F., Bruzzi, G., Cerri, S., Samarelli, A. V., Raineri, G., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02970-4 · Cited by 8
“Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) characterized by progressive parenchymal scarring, resulting in impaired pulmonary function and respiratory failure [1].”
BackgroundQuantitative micro-CT-derived biomarkers elucidate age-related lung fibrosis in elder mice
Buseghin, D., Grandi, A., Ferrini, E., Villetti, G., Ciccimarra, R., Sverzellati, N., Aliverti, A., Pennati, F., & Stellari, F. F. (2024) · Respiratory Research · doi:10.1186/s12931-024-03006-7 · Cited by 8
“Considering that IPF predominantly affects 65 years-old and elder individuals [2], the inclusion of aging-related factors in preclinical models might offer significant translational advantages in assessing the effectiveness of new antifibrotic therapies [7].”
BackgroundPhytoestrogen-Based Hormonal Replacement Therapy Could Benefit Women Suffering Late-Onset Asthma
Sommer, B., González-Ávila, G., Flores‐Soto, E., Montaño, L. M., Solís‐Chagoyán, H., & Romero-Martínez, B. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015335 · Cited by 9
Arginine methylation and respiratory disease
Zhang, B., Guan, Y., Zeng, D., & Wang, R. (2024) · Translational research · doi:10.1016/j.trsl.2024.03.002 · Cited by 5
Zou, M., Zheng, W., Hu, X., Gao, H., Hou, Q., Song, W., Liu, Y., & Cheng, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141890 · Cited by 7
Xue, S., Broerman, M. J., Goobie, G. C., Kass, D. J., Fabisiak, J. P., Wenzel, S. E., & Nouraie, M. S. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.4c11275 · Cited by 5
Shao, S., Cao, S., Chen, Y., Zhang, Z. T., & Tong, Z. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70072 · Cited by 5
Yang, Y., Huang, G., Zhang, T., Ling, Y., Jiang, J., Du, D., Ma, Y., & Tao, S. (2025) · Advanced Science · doi:10.1002/advs.202501718 · Cited by 8
Belmans, F., Persson, I. M., Bayat, S., Eaden, J. A., Vos, W. G., Jacob, J., Chambers, R. C., & Velde, G. V. (2025) · European Respiratory Review · doi:10.1183/16000617.0012-2025 · Cited by 7
“Variability in disease induction is indeed an important concern when investigating exacerbation of pulmonary fibrosis, an understudied yet highly relevant aspect of lung fibrosis research [23, 126, 127].”
In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model
Pitozzi, V., Caruso, P. L., Pontis, S., Pioselli, B., Ruscitti, F., Pittelli, M. G., Lagrasta, C. A. M., Quaini, F., Nogara, A. M., Aquino, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010064 · Cited by 5
“IPF affects the alveoli primarily before spreading to the surrounding lung tissue, which becomes thick and stiff, leading to irreversible architectural distortion [2].”
Wang, B., Fan, P., Guo, F., Song, Z., Zhang, Z., Lu, X., & Shi, J. (2026) · Science Advances · doi:10.1126/sciadv.ady1030 · Cited by 8
“Pirfenidone and nintedanib (Nint) are the only Food and Drug Administration–approved drugs for IPF ( 6 ); however, their clinical efficacy is limited by low oral bioavailability and poor lung-targeting capabilities ( 7 ).”
The importance of mechanical forces in chronic respiratory diseases
Burgess, J. K., Nawroth, J. C., Ibáñez‐Fonseca, A., & Gavara, N. (2026) · European Respiratory Review · doi:10.1183/16000617.0155-2025 · Cited by 10
“In connection to this, the onset of idiopathic pulmonary fibrosis (IPF) tends to take place in the subpleural space of the lower lung lobes [21, 22], corresponding to lung areas where alveoli are more greatly stretched during breathwork.”
Platenburg, M. G. J. P., Nakshbandi, G., Moor, C. C., van Batenburg, A. A., Mostard, R. L. M., Voortman, M., Moonen, L. A. A., Hekelaar, N., Overbeek, M. J., Bogaarts, B. A. H. A., et al. (2025) · Respirology · doi:10.1111/resp.70030 · Cited by 8
Pan, J., Khan, A. A., Yu, W.-K., & Rui, L. (2025) · BMC Palliative Care · doi:10.1186/s12904-025-01752-z · Cited by 5
“Emerging therapies, such as P2X3 inhibitors, have shown promise but remain investigational, leaving a significant gap in available accessible, non-invasive options [8, 22].”
Schreiber, J., Schütte, W., Koerber, W., Seese, B., Koschel, D., Neuland, K., & Grohé, C. (2024) · Pneumologie · doi:10.1055/a-2267-2074 · Cited by 6
Samarelli, A. V., Tonelli, R., Raineri, G., Mastrolia, I., Costantini, M., Fabbiani, L., Catani, V., Petrachi, T., Bruzzi, G., Andrisani, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12061321 · Cited by 6
“These include dysregulated wound healing in response to cyclic epithelial lung injury, fibroblast activation and proliferation with excessive extracellular matrix deposition (ECM), stem cell senescence, and genetic predisposition [4].”
BackgroundLian, H., Xu, K., Chang, A., Wang, Y., Ma, S., Cheng, L. C., Zhao, W., Xia, C., Wang, L., & Yu, G. (2024) · Respiratory Research · doi:10.1186/s12931-024-03041-4 · Cited by 6
“Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized high mortality and unclear pathogenesis [1].”
Bastos, V. A. F., Fujimura, P. T., de Souza, A. G., Vaz, E. R., Saito, N., Silva, R. S., Goulart, L. R., & Cunha, T. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062705 · Cited by 5
MUC5B Polymorphism in Patients with Idiopathic Pulmonary Fibrosis—Does It Really Matter?
Lewandowska, K. B., Lechowicz, U., Roży, A., Falis, M., Błasińska, K., Jakubowska, L., Franczuk, M., Żołnowska, B., Gryczka-Wróbel, J., Radwan-Röhrenschef, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052218 · Cited by 7
“Nevertheless, there are some known risk factors for developing the disease, like advanced age, male sex, cigarette smoking, and genetic predisposition [6,7].”
Ding, C., Zuo, R., Liao, Q., Guo, Z., He, J., Ye, Z., & Liu, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-04053-w · Cited by 4
Zhao, X., Kong, C., Xia, X., Zhao, K., Hao, M., Gao, Y., Wang, Y., Chen, Z., & Jiang, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102098 · Cited by 7
“Patients with PF typically have a survival expectancy of only 2 – 3 years, with a 5-year survival rate of less than 30 % [3].”
Yang, M., Fang, Y., Li, X., Yang, B., Ma, Q., Cui, X., Jiang, L., & Ge, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115385 · Cited by 4
Cao, Z., Wang, S. Y., Ma, J., Du, J., Wei, X., Yue, L., Zhang, J., Tan, Z., & Zhai, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02233 · Cited by 5
Qin, L., Zhao, B., Xiong, Y., Chen, L., Qi, S., Ma, Y., Zeng, H., Song, Y., Liu, W., Tian, T., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157607 · Cited by 5
Lee, J. Y., Yoon, S. H., Goo, J. M., Park, J., & Lee, J. H. (2024) · Respiratory Research · doi:10.1186/s12931-024-02712-6 · Cited by 5
“The clinical course of idiopathic pulmonary fibrosis (IPF) and the rate of disease progression are unpredictable and heterogeneous [1].”
BackgroundLi, Z., Zhang, M., Zhang, Y., Gan, Y., Zhu, Z., Wang, J., Yanlin, Z., Yu, G., & Wang, L. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00579-5 · Cited by 5
“The pathogenesis of PF is influenced by complex interactions between genetic and environmental factors [1, 3].”
Ye, H.-L., Meng, X.-Q., Li, H., Sun, X., Lin, W.-Z., Zhou, L.-J., Zhang, J., Hou, C., Xu, S., Chen, B., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1595500 · Cited by 7
“Idiopathic pulmonary fi brosis (IPF) is the most common and morbid type of idiopathic interstitial pneumonia (Podolanczuk et al., 2023).”
Divolis, G., Synolaki, E., Tringidou, R., Tzouvelekis, A., Boumpas, D. T., Skendros, P., & Galani, I. E. (2025) · Respiratory Research · doi:10.1186/s12931-025-03180-2 · Cited by 8
“…neutrophils with that of neutrophils isolated from patients with idiopathic pulmonary fibrosis (IPF), a non-viral chronic interstitial lung disease characterized by irreversible loss of lung function due to excessive extracellular matrix deposition and distortion of lung architecture [24–25].”
Shah, K. A., Ullah, S., Razzaq, A., Khan, M. N., Ali, T., Hussian, Y., Iqbal, H., & Cui, J.-H. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00441-w · Cited by 4
“Numerous studies indicate that the incidence and/or prevalence of PF has escalated with time, with one study revealing that the prevalence of PF doubled from 2000 to 2012 [3].”
Evaluation and management of chronic cough in adults
Wallace, D. V. (2023) · Allergy and Asthma Proceedings · doi:10.2500/aap.2023.44.230059 · Cited by 5
Tao, H., Lv, Q., Zhang, J., Chen, L., Yang, Y., & Sun, W. (2024) · Stem Cells International · doi:10.1155/2024/3429565 · Cited by 5
Wang, C., Chang, S., Hu, C.-F., Hu, Y.-Q., Luo, H., Liu, L., & Fan, L. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00913-9 · Cited by 4
“For example, familial pulmonary fibrosis accounts for 5–20% of IPF cases, with up to one-third of sporadic IPF cases having a family history of pulmonary fibrosis (Podolanczuk et al. 2023).”
BackgroundClark, K. P., Nouraie, M. S., Lindell, K. O., Gibson, K. F., Sciurba, F. C., Bon, J. M., & Kass, D. J. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202404-419oc · Cited by 6
Lopes, G. A. O., Lima, B. H. F., de Freitas, C. S., Peixoto, A. C., Soriani, F. M., Cassali, G. D., Ryffel, B., Teixeira, M. M., Machado, F. S., & Russo, R. C. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.70042 · Cited by 3
Cerri, S., Manzini, E., Nori, O., Pacchetti, L., Rossi, L., Turchiano, M. G., Samarelli, A. V., Raineri, G., Andrisani, D., Gozzi, F., et al. (2024) · Medicina · doi:10.3390/medicina60121967 · Cited by 7
Korytina, G. F., Markelov, V. A., Gibadullin, I. A., Рустэмович, З. Ш., Насибуллин, Т. Р., Zulkarneev, R., Avzaletdinov, A. M., Avdeev, S. N., & Zagidullin, N. S. (2025) · Biochemical Genetics · doi:10.1007/s10528-024-11012-z · Cited by 6
“This overlap may stem from the activation of shared signaling pathways (Podolanczuk et al. 2013; Lin et al. 2022; Yue et al. 2024).”
InfluentialSamarelli, A. V., Tonelli, R., Raineri, G., Bruzzi, G., Andrisani, D., Gozzi, F., Marchioni, A., Costantini, M., Fabbiani, L., Genovese, F., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1275346 · Cited by 5
Wang, M., Sun, Y., Zhao, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020517 · Cited by 3
“The median survival time following diagnosis is only 3–5 years, and the mortality rate of IPF is higher than that of several cancers [13,14].”
InfluentialMachine learning potential predictor of idiopathic pulmonary fibrosis
Ding, C., Liao, Q., Zuo, R., Zhang, S., Guo, Z., He, J., Ye, Z., Chen, W., & Ke, S. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2024.1464471 · Cited by 3
Trends and hotspots in pulmonary fibrosis biomarker research: a bibliometric analysis
Wang, L., Huang, J., Tan, G., Zhang, Y., Xia, M., Kang, Z., Xiao, Y., & Lei, M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1541364 · Cited by 4
“Second, while current pharmacological treatments can slow disease progression, they require ongoing assessment through regular physiological monitoring and serial imaging evaluations to adapt therapy dynamically (15).”
Zhang, Y., Cen, Z., Ding, Q., Ying, Y., Lv, C., & Wu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-08969-1 · Cited by 5
“One hundred ninety-four patients diagnosed with non-IPF fibrotic ILD, including idiopathic nonspecific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-associated ILDs, fibrotic hypersensitivity pneumonitis (FHP), microscopic polyangiitis (MPA)-associated ILD, and ILDs related to occupational exposures,…”
Royce, S. G., Erdem, C., Mao, W., Wang, Y., Borgo, M. P. D., Widdop, R. E., & Samuel, C. S. (2025) · Clinical Science · doi:10.1042/cs20245138 · Cited by 5
“It has a mortality rate of ~35–40% within three years and ~50–55% within five years of diagnosis, with women tending to have a slightly longer median survival time (3.9 years) compared with men (2.8 years) [6].”
InfluentialLi, W., Huang, Q., Li, M., Wen, Y., Chen, Z., Fan, Y., Shen, C., Chen, G., Luo, Y., & Deng, Z. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1644007 · Cited by 4
Salidroside alleviates the progression of idiopathic pulmonary fibrosis by regulating ferroptosis
Alharbi, H., Ahmad, M., Tu, L., et al. (2025) · Cytotechnology · doi:10.1007/s10616-025-00831-6 · Cited by 3
“Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial pneumonia of unknown etiology, characterized by recurrent acute lung injury that results in increased dyspnea and worsening lung function (Podolanczuk et al. 2023).”
Atmaca, S. N., Demir, R., Mustafaoğlu, R., & Atahan, E. (2025) · BioPsychoSocial Medicine · doi:10.1186/s13030-025-00346-8 · Cited by 3
“IPF causes a gradual decline in lung function, increased levels of dyspnea, dry cough, fatigue, decreased exercise capacity, and health-related quality of life [1].”
Wang, Y., Du, G., Zhang, J., Zhai, N., Liu, W., Cao, G., Li, H., Liu, B., Yang, H., Lv, C., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06166-5 · Cited by 4
Dual-Functional PDA@Au/CeO 2 Nanozymes Enable CT Tracking and Potent Antifibrotic MSC Therapy
Guan, S., Yao, Y., Ding, Y., Zhang, L., Huangfu, J., Chen, X., Wang, X., & Zhou, J. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18353 · Cited by 3
Chen, Y., Hu, L., Fu, Q., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121597 · Cited by 3
Morgan, A. D., Massen, G. M., Whittaker, H., Stewart, I. D., Jenkins, G. R., George, P. M., & Quint, J. K. (2025) · Pneumonia · doi:10.1186/s41479-024-00155-7 · Cited by 3
Wen, Y., Nie, J., Qin, X., & Li, Z. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116967 · Cited by 3
Advances in novel therapeutics for idiopathic pulmonary fibrosis
Li, M., Chen, B., Zhang, X., Zhuo, T., & Liu, X. (2025) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2025.102396 · Cited by 3
Lindell, K. O., Madisetti, M., Fasolino, T. K., et al. (2023) · Palliative Medicine Reports · doi:10.1089/pmr.2023.0038 · Cited by 3
Helou, D. G., & Crestani, B. (2024) · European Respiratory Journal · doi:10.1183/13993003.01954-2023 · Cited by 3
Bao, Y., Yang, S., Zhao, H., Wang, Y., Li, K., Liu, X., Zhang, W., & Zhu, X. L. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02976-0 · Cited by 4
“IPF is variable, unpredictable and significantly heterogeneous, and the rate of progression in a single patient in the short term is difficult to predict [3].”
BackgroundTsavlis, D., Domvri, K., Porpodis, Κ., Papoutsopoulou, S., Anestakis, D., Tzoumaka, A., Meditskou, S., Symeonidoy, K., & Spandou, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090972 · Cited by 4
“Although the Food and Drug Administration approved nintedanib and pirfenidone for the treatment of IPF in 2014, leading to a better prognosis by slowing down the progression of the disease, IPF is still incurable due to its complexity and not well-understood pathogenesis [2].”
BackgroundRautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03303-3 · Cited by 7
“Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease (ILD) that, despite recent research emphasis, remains incurable [1–4].”
BackgroundFBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis
Cheng, Y. W., Jiao, Y., Wei, W., Kou, M., Cai, Y., Li, Y., Li, H., & Liu, T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1509665 · Cited by 9
Liu, Y., Habibie, H., Borghuis, T., Liu, G., Hansbro, P. M., Melgert, B. N., & Burgess, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.05.626371 · Cited by 2
Wang, D., Yuan, Y., Tong, X., Wang, L., Sun, J., Zhang, S., Liu, S., Gan, H., & Fan, H. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s505229 · Cited by 2
Rao, X., Zhou, Y., Xue, J., & Zhou, Z. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108563 · Cited by 3
Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 7
Zhou, J., Xia, X., An, X., Liu, D., Zhao, H., Sun, Z., Li, W., & Huang, Q. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639043 · Cited by 5
“The incidence of IPF varies according to region, with 7–1,650 IPF cases per 100,000 people worldwide, and the annual incidence of IPF is increasing (3–5).”
Telomerase modRNA Offers a Novel RNA ‐Based Approach to Treat Human Pulmonary Fibrosis
Ye, J. L., Grieger, K. M., Lu, D., Brandenberger, C., Juchem, M., Jordan, M., Oehlsen, L., Zardo, P., Werlein, C., Hesse, C., et al. (2025) · Aging Cell · doi:10.1111/acel.70240 · Cited by 4
Xiao, C., Xie, Y., Liu, X., & Lei, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118717 · Cited by 4
Huang, X., Zhang, Y., Yan, X., Huang, Q., Chen, M., Jiang, C., Wang, Z., Sun, D., Li, Y., Ding, J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114427 · Cited by 3
The role of epigenetic regulation in idiopathic pulmonary fibrosis
Li, R. M., Stentenbach, M., Tan, D. B. A., Ludewick, H. P., Walters, E. H., Clynick, B., & Moodley, Y. P. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2025 · Cited by 3
Zhang, J., Zhou, J., Wang, Y., Yang, Y., Yue, T., & Chang, C. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100415 · Cited by 2
Exploring the role of PANoptosis in idiopathic pulmonary fibrosis based on scRNA-seq and bulk-seq
Wang, Z., Li, Q., Chen, Y., Gan, L., Yuan, L., Liu, J., Xie, Y., Zhou, T., & Ge, X. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01990-8 · Cited by 3
“Current treatment options primarily focus on antifibrotic therapies, which have shown limited efficacy, especially in the later stages of the disease [41].”
Inhalable stealth liposomes improve peptide delivery for pulmonary fibrosis treatment
Lin, R., Li, Z., Sun, Y., Shen, J., Cao, X., Lin, Y., Fu, C. L., Zhu, Y., Wang, C., Tan, Z., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114655 · Cited by 4
Li, X.-N., Ma, X.-X., Lin, Y.-P., Huang, B., Piao, J.-Y., Xu, H.-T., Xing, L., Jeong, J.-H., Cheng, X. W., Xu, Y., et al. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112480 · Cited by 2
Standalone prognostication of idiopathic pulmonary fibrosis using attention-based deep learning
Lee, J. H., Chae, K. J., Lee, H. S., Park, J., Choi, S. M., Goo, J. M., & Kim, H. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag098 · Cited by 3
Zheng, C., Ding, W., Sun, Y., Wang, Y., & Zhang, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s576680 · Cited by 3
“Although PFD and NIN have been approved by the FDA and can slow disease progression to some extent, 7,10 their therapeutic efficacy remains limited due to disease heterogeneity, insufficient potency, and dose-related AEs.”
Thymic stromal lymphopoietin (TSLP) – pro-inflammatory cytokine and antimicrobial peptide
Döhner, K., John, O. P., & Werfel, T. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120127 · Cited by 8
Kaburaki, S., Tanaka, T., Kamio, K., Tanaka, Y., Taniuchi, N., Kasahara, K., & Seike, M. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag069 · Cited by 2
Makovická, M., Vrbenská, A., Makovický, P., et al. (2024) · General Physiology and Biophysics · doi:10.4149/gpb_2023029 · Cited by 2
Biogenesis and Function of circRNAs in Pulmonary Fibrosis
Zhang, S., Hu, W., Lv, C., & Song, X. (2024) · Current Gene Therapy · doi:10.2174/0115665232284076240207073542 · Cited by 3
Genetic factors for ILD—the path of precision medicine
Raghu, G., Torres, J. M., & Bennett, R. L. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00071-7 · Cited by 5
“1,2 Given that IPF is known to a be a progressive fibrotic ILD, the term progressive pulmonary fibrosis (PPF) was defined in 2022 to recognise progressive fibrotic ILD in patients with ILDs other than IPF.”
Self-citationIdentification of non-coding RNA signatures in idiopathic pulmonary fibrosis
Elek, A., Bozgeyik, E., Caska, H., Gocer, Z., & Bozgeyik, İ. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-024-03675-9 · Cited by 4
A nonsense mutation (c.382C>T) of PARN in a patient with idiopathic pulmonary fibrosis
Wang, C.-Y., Liu, L., Peng, H., et al. (2024) · QJM · doi:10.1093/qjmed/hcae069 · Cited by 2
Were deaths recorded in Brazil due to cystic fibrosis or pulmonary fibrosis? A data-based analysis
Marques, L. S., Firmida, M. D. C., & Marson, F. A. L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1459785 · Cited by 3
Chen, Y., Cao, S., Shao, S., & Tong, Z. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03289-y · Cited by 3
“…drug targets for idiopathic pulmonary fibrosis Yusha Chen 1,2 , Siyu Cao 1,2 , Shuai Shao 1,2 and Zhaohui Tong 1,2* Background Idiopathic Pulmonary Fibrosis (IPF) stands as a debilitating interstitial lung disease characterized by progressive respiratory failure and physiological impairment [1].”
BackgroundCavasin, D., Zanini, U., Montelisciani, L., Valsecchi, M. G., Fabbri, L., Antolini, L., & Luppi, F. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.3070 · Cited by 2
Carlson, L., Kalafatis, D., Pesonen, I., Magnusson, J. M., & Sköld, M. C. (2024) · Chronic Respiratory Disease · doi:10.1177/14799731241299443 · Cited by 3
Ge, S., Li, Y., Li, R., Liu, J., Zhang, R., Fu, H., Tang, J., Zhang, J., Zhang, N., & Zhang, M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1497530 · Cited by 2
Bioimpedance measurements of fibrotic and acutely injured lung tissues
Mir, M., Chen, J., Patel, A., Pinezich, M. R., Hudock, M. R., Yoon, A., Diane, M., O’Neill, J. D., Bacchetta, M. D., Vunjak‐Novakovic, G., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.01.039 · Cited by 5
Ji, Q., Jiang, L., Gao, F., & Hou, J. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01571-8 · Cited by 2
“IPF is characterized by significant heterogeneity and complex cellular interactions, posing challenges for effective treatment (Podolanczuk et al. 2023).”
Identification of diagnostic hub genes related to energy metabolism in idiopathic pulmonary fibrosis
Zhao, S., Sun, B., Liu, N., Huo, R., Liu, L. S., Wang, J. P., & Fang, C. Y. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1596364 · Cited by 4
Liu, X., Jun-mei, S., Guo, S., Liao, Y., Zou, J., Yang, L., & Jiang, C. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03876-0 · Cited by 4
“Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown origin, characterized by abnormal alveolar repair that triggers excessive myofibroblast proliferation and extracellular matrix (ECM) accumulation, leading to fibrosis and functional impairment of lung tissue [1, 2].”
Targeting E3 ubiquitin ligases: a new frontier in idiopathic pulmonary fibrosis treatment
Zhang, K., Yuan, H., & Shi, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1618424 · Cited by 6
Zhu, H., Chen, C., Guo, H., Zhang, B., & Hu, Q. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70120 · Cited by 4
Yin, Y., Jia, N., Luo, H., Feng, X. L., He, X., Huang, J., & Wang, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1666698 · Cited by 3
Zhou, S., Dong, Y.-X., Tian, J., Che, G., & Lai, Y. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.09.005 · Cited by 3
Zhang, L., Yu, L., Deng, D., Liang, Q., Du, H., Mei, M., Deng, C., Song, J., & Guo, W. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120717 · Cited by 5
Interstitial lung disease-associated pulmonary hypertension – what the future holds
Cottin, V., Diesler, R., Turquier, S., & Valenzuela, C. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000992 · Cited by 2
“fibrotic interstitial lung diseases (fILD) with a progressive phenotype (progressive pulmonary fibrosis despite appropriate management) are characterized by relentless, progressive course of disease, leading to chronic respiratory failure and early mortality [1,2].”
BackgroundSun, D., & Ye, Q. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02788-8 · Cited by 4
“For FVC, DLco, and TFS in patients with IPF, potential confounders included pulmonary function testing, pollution, occupation, and pulmonary infection (excluded previous exposures) [1, 31].”
Background
Metadata
- Authors
- Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G.
- Affiliations
- Weill Cornell Medicine (US)
- Mount Auburn Hospital (US)
- Università Cattolica del Sacro Cuore (IT)
- St. Joseph’s Healthcare Hamilton (CA)
- University of Washington (US)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2023-01-26
- Volume
- 61
- Issue
- 4
- Pages
- 2200957
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4318071623
- Cited by
- 359
- References
- 196
- Citations by year
- 2026: 112 · 2025: 126 · 2024: 101 · 2023: 20
- FWCI
- 65.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, lung function decline, disease progression, natural history (disease), pathobiology, genetic risk factors, comorbidities, patient monitoring, palliative care, lung transplantation, early detection, diagnosis
- MeSH terms
- Aged, Humans, Tomography, X-Ray Computed, Lung Transplantation, Disease Progression, Early Diagnosis, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.